AMGEN Inc
NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024
AMGN Articles
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
Jon OggAmgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that is the case brought by Third Point LLC and...
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
Through August, planned job cuts were slightly lower than they were during the first eight months of 2013. In all, companies have announced just under 333,000 planned layoffs so far this year, down...
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy for the rest of this year and 2015, and the analysts keep the answers short and...
Published:
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Published:
ThinkstockMost firms we cover on Wall Street have quantitative strategies for their clients, and often they use similar formulas to arrive at what belongs in the top quintile versus the bottom. Cash...
Published:
This week's layoff announcement by Amgen may have investors and the public starting to rethink what "being a biotech company" really means.
Published:
ThinkstockA brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The...
Published:
New research reports from the biotech, health care and medical device teams at Deutsche Bank raise price targets on three top names to buy and include updates on two others.
Published:
In a research note, Leerink analysts mentioned four specific top biotech names that may have the ability to beat current earnings expectations. But 24/7 Wall St. has one caveat.
Published: